Clinical Trials Directory

Trials / Completed

CompletedNCT00799045

Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
220 (actual)
Sponsor
Laval University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The addition of clopidogrel on top of aspirin may reduce the occurrence of new-onset migraine headache episodes following transcatheter ASD closure.

Detailed description

The objective is to evaluate the incidence and severity of new-onset migraine headache episodes following transcatheter ASD closure in patients treated with aspirin alone compared to those on aspirin + clopidogrel therapy as antithrombotic treatment after the procedure. This is a prospective, randomized, double blind, multicenter study, including patients with no previous history of migraine attacks who have been diagnosed with an ASD and for whom transcatheter ASD closure has been clinically indicated. Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure. The occurrence and severity of migraine headaches will be evaluated by a neurologist using a structured headache questionnaire at 1 month and 3 months following ASD closure. An additional 6 month and 1 year follow-up evaluation will be exploratory according to local feasibility.

Conditions

Interventions

TypeNameDescription
DRUGClopidogrelPatients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.

Timeline

Start date
2008-10-01
Primary completion
2015-04-01
Completion
2016-12-01
First posted
2008-11-27
Last updated
2019-02-26

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT00799045. Inclusion in this directory is not an endorsement.